Ocuphire Pharma ROE 2010-2024 | IRD
Current and historical return on equity (ROE) values for Ocuphire Pharma (IRD) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Ocuphire Pharma ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.01B |
$0.04B |
-29.95% |
| 2024-03-31 |
$-0.01B |
$0.05B |
-23.91% |
| 2023-12-31 |
$-0.01B |
$0.05B |
-22.35% |
| 2023-09-30 |
$0.03B |
$0.05B |
66.29% |
| 2023-06-30 |
$0.02B |
$0.04B |
52.55% |
| 2023-03-31 |
$0.02B |
$0.04B |
63.16% |
| 2022-12-31 |
$0.02B |
$0.05B |
75.56% |
| 2022-09-30 |
$-0.02B |
$0.01B |
-139.39% |
| 2022-06-30 |
$-0.02B |
$0.02B |
-117.33% |
| 2022-03-31 |
$-0.02B |
$0.02B |
-115.66% |
| 2021-12-31 |
$-0.06B |
$0.02B |
-294.74% |
| 2021-09-30 |
$-0.07B |
$0.02B |
-673.17% |
| 2021-06-30 |
$-0.07B |
$0.02B |
-1015.38% |
| 2021-03-31 |
$-0.06B |
$0.01B |
-2440.00% |
| 2020-12-31 |
$-0.03B |
$-0.01B |
-1111.11% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-142.86% |
| 2020-06-30 |
$-0.01B |
$0.01B |
-120.00% |
| 2020-03-31 |
$-0.01B |
$0.01B |
-88.89% |
| 2019-12-31 |
$-0.01B |
$-0.01B |
-58.82% |
| 2019-09-30 |
$-0.01B |
$0.01B |
-67.92% |
| 2019-06-30 |
$-0.01B |
$0.01B |
-102.13% |
| 2019-03-31 |
$-0.01B |
$0.02B |
-127.27% |
| 2018-12-31 |
$-0.01B |
$0.01B |
-130.23% |
| 2018-09-30 |
$-0.02B |
$0.01B |
-122.45% |
| 2018-06-30 |
$-0.01B |
$0.01B |
-75.86% |
| 2018-03-31 |
$-0.01B |
$0.02B |
-38.10% |
| 2017-12-31 |
$-0.03B |
$0.02B |
-212.24% |
| 2017-09-30 |
$-0.02B |
$0.02B |
-187.76% |
| 2017-06-30 |
$-0.03B |
$0.02B |
-196.08% |
| 2017-03-31 |
$-0.03B |
$0.00B |
-219.61% |
| 2016-12-31 |
$-0.01B |
$0.02B |
-59.70% |
| 2016-09-30 |
$-0.01B |
$0.02B |
-69.57% |
| 2016-06-30 |
$-0.01B |
$0.02B |
-74.29% |
| 2016-03-31 |
$-0.01B |
$0.02B |
-74.67% |
| 2015-12-31 |
$-0.01B |
$0.02B |
-69.14% |
| 2015-09-30 |
$-0.01B |
$0.02B |
-58.43% |
| 2015-06-30 |
$-0.01B |
$0.02B |
-44.00% |
| 2015-03-31 |
$-0.01B |
$0.02B |
-29.36% |
| 2014-12-31 |
$-0.02B |
$0.03B |
-66.67% |
| 2014-09-30 |
$-0.02B |
$0.03B |
-80.00% |
| 2014-06-30 |
$-0.02B |
$0.03B |
-98.77% |
| 2014-03-31 |
$-0.02B |
$0.03B |
-161.40% |
| 2013-12-31 |
$-0.01B |
$0.01B |
-108.11% |
| 2013-09-30 |
$-0.01B |
$0.01B |
-82.35% |
| 2013-06-30 |
$-0.01B |
$0.01B |
-110.34% |
| 2013-03-31 |
$-0.01B |
$0.01B |
-77.42% |
| 2012-12-31 |
$-0.01B |
$0.01B |
-75.00% |
| 2012-09-30 |
$-0.01B |
$0.01B |
-72.73% |
| 2012-06-30 |
$-0.00B |
$0.01B |
-42.11% |
| 2012-03-31 |
$-0.01B |
$0.01B |
-87.80% |
| 2011-12-31 |
$-0.01B |
$0.01B |
-89.80% |
| 2011-09-30 |
$-0.01B |
$0.01B |
-116.67% |
| 2011-06-30 |
$-0.01B |
$0.01B |
-96.30% |
| 2011-03-31 |
$-0.01B |
$0.02B |
-73.33% |
| 2010-12-31 |
$-0.02B |
$0.01B |
-117.65% |
| 2010-09-30 |
$-0.01B |
$0.02B |
-86.96% |
| 2010-06-30 |
$-0.01B |
$0.02B |
-125.71% |
| 2010-03-31 |
$-0.01B |
$0.01B |
-171.43% |
| 2009-12-31 |
$-0.00B |
$0.01B |
-53.33% |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
